Swiss National Bank Grows Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Swiss National Bank lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 2.7% during the fourth quarter, Holdings Channel reports. The fund owned 110,600 shares of the company’s stock after purchasing an additional 2,900 shares during the quarter. Swiss National Bank’s holdings in Pacira BioSciences were worth $4,270,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Congress Asset Management Co. MA increased its holdings in Pacira BioSciences by 0.7% in the fourth quarter. Congress Asset Management Co. MA now owns 77,774 shares of the company’s stock valued at $3,003,000 after buying an additional 574 shares during the last quarter. Tudor Investment Corp Et Al bought a new stake in Pacira BioSciences in the third quarter valued at about $937,000. Gradient Investments LLC increased its holdings in Pacira BioSciences by 26.3% in the fourth quarter. Gradient Investments LLC now owns 71,747 shares of the company’s stock valued at $2,770,000 after buying an additional 14,938 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in Pacira BioSciences by 7.2% in the fourth quarter. Rice Hall James & Associates LLC now owns 437,285 shares of the company’s stock valued at $16,884,000 after buying an additional 29,407 shares during the last quarter. Finally, Martingale Asset Management L P increased its holdings in Pacira BioSciences by 11.8% in the third quarter. Martingale Asset Management L P now owns 33,213 shares of the company’s stock valued at $1,768,000 after buying an additional 3,501 shares during the last quarter.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $40.84 on Friday. The company’s fifty day moving average is $42.07 and its two-hundred day moving average is $42.45. The company has a quick ratio of 2.87, a current ratio of 3.81 and a debt-to-equity ratio of 0.71. Pacira BioSciences, Inc. has a 12-month low of $35.35 and a 12-month high of $65.71. The company has a market cap of $1.88 billion, a P/E ratio of -151.26 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX – Get Rating) last announced its earnings results on Wednesday, May 3rd. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.08). Pacira BioSciences had a negative net margin of 1.56% and a positive return on equity of 10.12%. The firm had revenue of $160.34 million for the quarter, compared to analyst estimates of $157.02 million. Equities analysts expect that Pacira BioSciences, Inc. will post 2.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

PCRX has been the subject of several research analyst reports. HC Wainwright boosted their price objective on Pacira BioSciences from $69.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday, March 1st. StockNews.com assumed coverage on Pacira BioSciences in a research note on Thursday. They issued a “hold” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Pacira BioSciences in a research note on Thursday, April 20th. Barclays reduced their price objective on Pacira BioSciences from $90.00 to $80.00 in a research report on Friday, March 3rd. Finally, Piper Sandler reduced their price objective on Pacira BioSciences from $63.00 to $62.00 in a research report on Tuesday, April 25th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.73.

Insider Buying and Selling

In other Pacira BioSciences news, Director Gary W. Pace sold 5,015 shares of the stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $41.78, for a total transaction of $209,526.70. Following the transaction, the director now directly owns 139,675 shares of the company’s stock, valued at $5,835,621.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.60% of the stock is owned by corporate insiders.

Pacira BioSciences Company Profile

(Get Rating)

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.